Novavax Says Updated XBB.1.5 COVID-19 Vaccine Showed Robust Neutralizing Antibody Titers
(RTTNews) - Novavax, Inc. (NVAX) announced Monday that new data from Novavax's ongoing research on its updated XBB.1.5 COVID-19 vaccine in participants who previously received an mRNA vaccine showed robust neutralizing antibody titers for the XBB.1.5 subvariant as well as for the currently circulating JN.1 subvariant.
The data also showed that the vaccine's safety and reactogenicity profile was consistent with its prototype vaccine (NVX-CoV2373).
read more
Novavax Says Taiwan Grants EUA For Nuvaxovid XBB.1.5 Dispersion For Injection COVID-19 Vaccine
Novavax, Inc. (NVAX) announced Monday that the Taiwan Food and Drug Administration has granted emergency use authorization for Nuvaxovid XBB.1.5 dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) for active immunization to prevent COVID-19 in individuals aged 12 and older.
RTTNews
|
386 days ago
Novavax Appoints John Trizzino To Take On Newly Created Role Of President And COO
Vaccine maker Novavax, Inc. (NVAX) announced Friday changes to its executive leadership team designed to enhance focus on its strategic priorities and continue the evolution of the Company's scale and structure announced last week.
RTTNews
|
417 days ago
Novavax Slashes FY23 Total Revenue Outlook - Update
While reporting financial results for the third quarter on Thursday, Novavax, Inc. (NVAX) slashed its revenue guidance for the full-year 2023, accounting for some revenue shifting into first quarter of fiscal 2024. The company also provided revenue forecast for the first quarter of fiscal 2024.
RTTNews
|
425 days ago
Novavax's Nuvaxovid Gets Full Marketing Authorization In EU To Prevent COVID-19
Novavax, Inc. (NVAX) on Thursday has been granted full Marketing Authorization (MA) by the European Commission in the European Union (EU) for Nuvaxovid (NVX-CoV2373).
RTTNews
|
551 days ago
Novavax Says Nuvaxovid Recommended For Full Marketing Authorization For COVID In EU
Biotechnology company Novavax, Inc. (NVAX) announced Friday that Nuvaxovid (NVX-CoV2373) has been recommended for full Marketing Authorization (MA) for use as a primary series in individuals aged 12 and older and as a booster in individuals aged 18 and older for the prevention of COVID-19 in the European Union (EU).
RTTNews
|
592 days ago
Singapore HSA Extends Interim Authorization To Novavax's COVID Vaccine For Adolescents
Novavax, Inc. (NVAX) announced Friday that the Singapore Health Sciences Authority (HSA) has granted extended interim authorization and the Ministry of Health has included Nuvaxovid (NVX-CoV2373) into the National Vaccination Program as a non-mRNA option for adolescents aged 12 through 17 for active immunization to prevent COVID.
RTTNews
|
606 days ago
Novavax Extends Partnership With U.S. Health Dept. To Deliver 1.5 Mln Addl Doses Of NVX-CoV2373
Biotechnology company Novavax, Inc. (NVAX) announced Monday a modification to its existing agreement with the U.S. Department of Health and Human Services (HHS), in collaboration with the Department of Defense, to deliver up to 1.5 million doses of the Novavax COVID-19 Vaccine, Adjuvanted (NVX-CoV2373).
RTTNews
|
694 days ago
Novavax Appoints John Jacobs To Succeed Stanley Erck As President And CEO
Biotechnology company Novavax, Inc. (NVAX) announced that John Jacobs will succeed Stanley Erck as President and Chief Executive Officer and a member of the Board of Directors, effective as of January 23, 2023. Erck will serve as an advisor to the Company for the next fifteen months to enable a smooth transition.
RTTNews
|
729 days ago
